Amarin Corp Plc (AMRN)

[Atom0aks]

So 4.8% primary endpoint risk reduction over median 4.9 years.

And we're talking about 3 months (.25 years)

So if the delay kept a million people off V for 3 months, you'd expect the following event reduction

1,000,000 x .048 x .25/4.9

That's 2,448 events

Of which about ~20% would be CV deaths (maybe a little less) -- call it 15% for conservatism -- so ~367 events

But of course you have to look at ultimate usage levels, not upfront

If ultimately 20 million people globally are on V, and this delay pushed that out 3 months, then you're talking 20x that death count

Thanks for the assist! But I was intentionally trying to avoid estimations, because as I pointed out in my response JL, there are so many variables to consider in order to accurately know how many people would be prescribed Vascepa in 3 months.